Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

#Incretin mimetics

GLP-1, GIP, glucagon receptor agonists.

Explainer

New Model Explains Tirzepatide's Edge

A modeling study traces tirzepatide's fasting-glucose advantage over semaglutide to greater liver glucose suppression, not beta cells or extra weight loss.

21 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

MASLD Screening Without a Liver Biopsy

A new review explains how FIB-4 screens for MASLD and MASH in primary care, now that semaglutide and resmetirom can treat confirmed cases.

19 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Why semaglutide alone beat the CRV431 combo

In a mouse model of advanced liver disease, semaglutide alone reduced tumor burden more than adding the investigational compound CRV431.

19 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide and eyelid styes: what's known

A two-patient case series reports recurring eyelid styes and chalazia after tirzepatide, with one positive rechallenge.

19 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 Drugs and Lumbar Fusion Surgery

A new meta-analysis found no significant link between GLP-1 drugs like semaglutide and complications after lumbar fusion surgery.

18 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide After Pancreatitis: A Case

A new case report describes semaglutide controlling refractory hypertriglyceridemia after six pancreatitis episodes.

18 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Obesity care outside trials

A new review examines how access, tolerability, persistence, and support can shape anti-obesity treatment outcomes in routine care.

16 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 use before bariatric surgery

A matched retrospective study linked prior GLP-1RA or tirzepatide use to lower recorded early cardiorenal events after bariatric surgery.

16 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide ASCVD cost model

A US veteran model found lifetime semaglutide added 1.31 QALYs but cost $118,996 per QALY at an assumed $14,000 annual price.

15 Sept 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide and Work: Survey Findings

A survey of 518 US employees starting tirzepatide found strong support for obesity-drug coverage, but it did not measure treatment effects.

14 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide and Exercise Anaphylaxis

A case report links tirzepatide with exercise-induced anaphylaxis in one patient, with no recurrence after the medicine was stopped.

14 Sept 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

How GLP-1 Analogs Are Engineered

A 2026 review explains how GLP-1 analogs use sequence changes, peptide shape and lipidation to resist breakdown and last longer.

13 Sept 2026 · PeptideMethods Editorial Team · 4 min read